CD8A and neoplasm: To verify the role of immune cells in the robust antitumor efficacy of anti–PD-1 plus TRACER, we depleted CD8+ T cells or NK cells in mice bearing a B16F10 tumor on day 14, one day after the final treatment, and monitored tumor growth for 50 days (Figure 4A).